SK pharmteco Opens New CGMP Plasmid Suite in King of Prussia

• SK pharmteco has opened a CGMP plasmid suite in King of Prussia to strengthen its cell and gene therapy service offerings.

• The facility provides integrated CDMO services including plasmid production, fill & finish, and analytical testing.

SK pharmteco, a global contract development and manufacturing organization (CDMO), has announced the launch of a new CGMP plasmid suite at its King of Prussia, Pennsylvania facility. The expansion is aimed at increasing the supply of high-quality plasmids used in cell and gene therapy (CGT) development.

The new suite is located within SK pharmteco’s 300,000 sq. ft. facility, which also houses four dedicated plasmid manufacturing suites and supports three distinct plasmid grades. The site includes two aseptic fill & finish operations, contract analytical testing, and an in-house CGMP cell line.

Plasmids are essential starting materials for viral vector production and CGT manufacturing. The company highlighted the strategic location of the facility within a biopharma innovation hub and its potential to support clients developing therapies for unmet medical needs.

“This new CGMP plasmid suite in King of Prussia represents a solid investment in our capabilities and our commitment to the cell and gene therapy sector,” said Joerg Ahlgrimm, Chief Executive Officer at SK pharmteco.

The expansion comes at a time when the CGT sector is facing challenges around reimbursement and access due to high upfront costs of therapies. The substantial upfront costs of these therapies—ranging from $500,000 to $3.5 million—pose major barriers to broad patient access. SK pharmteco’s investment aims to support growth in the field by ensuring a stable supply of critical materials.